SLC5A2 and chronic kidney disease: One such an example is sodium-glucose cotransporter-2 inhibitors (SGLT-2i); in Japan, the SGLT-2i dapagliflozin was approved in 2021 for the treatment of CKD with or without type 2 diabetes.